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Abstract 
Background: In Australia, where direct to consumer advertising of prescription medicines is prohibited, 
pharmaceutical companies can sponsor disease awareness advertising targeting consumers. This study 
examined the impact of disease awareness advertising exposure on older women's reported behavioural 
intentions. Method: Women were approached in a shopping centre and randomly assigned mock 
advertisements for two health conditions. Disease information and sponsors were manipulated. Results: 
Two hundred and forty-one women responded to 466 advertisements. Almost half reported an intention 
to ask their doctor for a prescription or referral as a result of seeing the advertisement, but more reported 
they would talk to their doctor and ask about treatments and tests. Participants were more likely to report 
an intention to ask for prescriptions if they perceived the health condition to be severe and themselves 
susceptible or if they had viewed advertisements containing limited information on the disease. 
Discussion: Disease awareness advertising may stimulate demand for prescription medicine products. 
This has serious implications for general practitioners and regulators 
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There is growing concern from advisory 
and advocacy groups in Australia, as 
well as in other countries, regarding the 
influence of the pharmaceutical industry 
on the prescribing habits of doctors.1,2 
Concern has centred around marketing 
practices that directly influence doctors’ 
prescribing behaviour,3,4 as well as 
pharmaceutical promotions that directly 
target consumers.5,6
While direct-to-consumer advertising (DtcA) 
of prescription medicines is illegal in Australia, 
pharmaceutical companies are allowed to engage 
in disease awareness advertising (DAA) via a 
range of media. Disease awareness advertising 
in Australia is currently regulated by the industry 
body medicines Australia. Edition 16 of the code 
of conduct recently came into effect with a specific 
section (section 12.7) on ‘Disease education 
activities in any media’.7 the guidelines state 
that advertisements cannot include the name of 
a specific prescription medicine but may include 
disease information such as the symptoms and 
prevalence of a disease.7
 international research into the effects of DAA 
demonstrate that it can increase consultation 
rates as well as prescriptions for the advertiser’s 
product.8,9 A recent survey of Australian general 
practitioners10 reported in the popular medical 
press found a pharmaceutical mass media 
campaign coincided with increased patient 
requests about the advertiser’s product.
 Disease awareness advertising has been 
labelled as disease mongering – ‘widening 
boundaries of treatable illness in order to expand 
markets for those who profit from treatments’.3 
Disease awareness advertising has been criticised 
for promoting health conditions with vague 
or nonspecific symptoms, or exaggerating the 
prevalence of a condition and using fear appeals, 
such that consumers are encouraged to identify 
themselves as having the condition or being at 
greater risk of contracting it.1 While DAA can be 
eye catching and emotive, it often provides very 
limited disease information,11 which is the same 
criticism received by DtcA.12
 the pharmaceutical industry, and its 
proponents, argue that advertising to consumers 
provides education about health conditions 
and treatment options, and can assist in earlier 
diagnosis and treatment, improved patient-
doctor relationships, and enhanced medication 
compliance.13,14 there is also the argument of 
the potential for the pharmaceutical industry 
to advertise conditions that have high levels of 
underdiagnosis such as diabetes.15
 the purpose of this study was to determine the 
impact of DAA on the behavioural intentions of 
older Australian women, including their intention 
to seek further information, and/or request a 
prescription or referral from their doctor. the study 
also examined perceptions of the severity of, 
and their susceptibility to, two advertised health 
conditions.
Method
the study design included the development of mock 
magazine advertisements for two health conditions 
(Figure 1). Women were selected as the target 
group as they have higher magazine readership in 
Australia and generally have greater involvement 
in seeking health information and making health 
decisions. the age range of 45 years or over was 
chosen to facilitate the selection of targeted health 
conditions for the advertisement stimuli.
 the health conditions were osteopaenia, which 
is a state of early bone loss that can potentially 
increase the risk of developing osteoporosis;16 
and fibromyalgia, which is thought to be a 
disorder of the central nervous system associated 
with intensified pain due to abnormal sensory 
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In Australia, where direct to consumer 
advertising of prescription medicines is 
prohibited, pharmaceutical companies 
can sponsor disease awareness 
advertising targeting consumers. This 
study examined the impact of disease 
awareness advertising exposure on 
older women’s reported behavioural 
intentions. 
Method
Women were approached in a 
shopping centre and randomly 
assigned mock advertisements for two 
health conditions. Disease information 
and sponsors were manipulated. 
Results
Two hundred and forty-one women 
responded to 466 advertisements. 
Almost half reported an intention to ask 
their doctor for a prescription or referral 
as a result of seeing the advertisement, 
but more reported they would talk to 
their doctor and ask about treatments 
and tests. Participants were more 
likely to report an intention to ask for 
prescriptions if they perceived the health 
condition to be severe and themselves 
susceptible or if they had viewed 
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information on the disease.
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is some evidence for treatment with prescription 
medicines including amitriptyline, fluoxetine as 
well as serotonin and norepinephrine reuptake 
inhibitors; however, a multidisciplinary approach 
including patient education is recommended.22 
Prescription medicine advertising for the treatment 
of fibromyalgia (eg. pregabalin) has occurred in the 
usA;18 the growing recognition of the condition in 
Australia suggests it could be a target country for 
disease advertising by pharmaceutical companies.
 the mock advertisements included similar 
images and quantity of text as is found in current 
DAA in Australian magazines.12 two different 
manipulations were applied to the advertisements: 
the amount of information provided and the 
sponsor logos. For the information manipulation, 
participants received either limited information 
(brief descriptions of the symptoms, and how 
to seek further information) or more detailed 
information (fuller descriptions of the symptoms, 
causation, diagnosis and management as well as 
how to seek further information). For the sponsor 
manipulation, fictional logos at the bottom of 
processing.17 Both conditions have been subject 
to controversy regarding their clinical importance, 
and there is concern that they may attract disease 
mongering.18,19 the authors were not able to find 
evidence of education or promotion targeting 
consumers about these conditions in Australia.
 there are three potential prescription medicine 
categories for the prevention of osteoporosis 
in postmenopausal women, and Australian 
clinical guidelines recommend the use of two 
of these for reducing the risk of osteoporotic 
fractures by increasing bone mineral density in 
postmenopausal women at risk.20 it is therefore 
feasible that pharmaceutical companies would 
sponsor Australian awareness advertising about 
osteopaenia to encourage women to undertake 
bone density testing and preventive treatment, 
as has occurred in the united states of America 
(usA).19,21
 there are no specific Australian guidelines 
for diagnosis or management of fibromyalgia, 
although the American college of Rheumatology 
classification criteria are commonly used.22 there 
the advertisement varied between nonprofit, 
pharmaceutical company and a combination of 
these two (cosponsored). 
 Research assistants approached women in a 
commercial shopping centre in the Wollongong 
(new south Wales) metropolitan area during retail 
hours over 5 consecutive days in november 2008. 
Refusals and ineligible respondents were recorded. 
 consenting participants were randomly 
assigned an advertisement for one health condition 
and then received an advertisement for the other 
health condition with the same sponsor and with 
information manipulation. Participants viewed the 
advertisements and completed the questionnaires 
independently and were debriefed regarding the 
hypothetical nature of the advertisements. 
 this study was approved by the university of 
Wollongong human Research Ethics committee. 
 A score was created for perceived severity of 
the condition, which included responses to three 
bipolar adjective scales for how ‘distressing, 
serious and inconvenient’ it would be to experience 
the condition. cronbach’s alpha for the three item 
Osteopenia is a state of early bone loss which can increase your risk of
developing osteoporosis and future bone fractures.
It is of particular concern if you are over 60 years of age or
post-menopausal with a family history of osteoporosis.
What is Osteopenia?
Osteopenia is a condition that describes lower bone mass and is a state which may
precede osteoporosis. There are no obvious symptoms for osteopenia. Women over 60
years of age, and post-menopausal women with a family history of osteoporosis are at
greater risk.
What is Osteoporosis?
Osteoporosis is a disease in which the density and quality of bone are reduced, leading
to bone weakness and increased risk of fracture, particularly of the spine, wrist and hip.
Two million Australians are affected by osteoporosis, and every 8 minutes someone is
admitted to hospital with a fracture.
Diagnosis and Management of Osteopenia
Women at risk of osteopenia can arrange for a bone-density test through their doctor or
other health provider to determine their bone density score. If they have osteopenia then
there are a range of ways to manage the condition including increasing calcium intake
and increasing strength-building exercise.
Treatment
Women with osteopenia can talk to their doctor about new and effective medicines
which restore minerals to bones and help prevent the onset of osteoporosis.
For more information go to www.osteopenia.com.au




Zuerst Pharmaceuticals Pty. Ltd. ABN 95 000 180 999. Unit 32 Times Square Industrial Park, Point Cook VIC 3030.
Understanding Osteopenia...
Are you over 60 or post-menopausal with a family history
of osteoporosis?
It may be that you have osteopenia or early bone loss which
can increase your risk of developing osteoporosis and
future bone fractures.
To see if you have osteopenia you need to take a bone density test,
available at many pharmacies. If your bone density test score is low
then you should talk with your doctor.
Your doctor can advise about new and effective medicines to treat
osteopenia that help prevent the onset of osteoporosis.
Forget about future fractures.
ZUERST Pharmaceuticals.
Zuerst Pharmaceuticals Pty. Ltd. ABN 95 000 180 999. Unit 32 Times Square Industrial Park, Point Cook VIC 3030.
For more information visit www.osteopenia.com.au




Figure 1. Mock magazine advertisements for osteoporosis and osteopenia
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of participants estimated that it was very likely that 
they would experience fibromyalgia in the future, 
whereas 36% estimated that it was very likely that 
they would experience osteopaenia. Participants 
who nominated an intention to ask their doctor for 
a prescription or a referral were significantly more 
likely to perceive higher susceptibility to the health 
conditions (mean score 4.14 compared with 3.12 
for participants who did not intend to ask: p<0.001) 
and have higher severity scores (mean score of 4.77 
compared with 4.28: p<0.001). 
Discussion 
Participants who viewed the advertisements 
with less disease information were more likely 
to express an intention to ask their doctor for a 
prescription or a referral. this finding may concern 
GPs as it indicates the potential for industry DAA 
to stimulate patient requests for prescription 
medicines – this has been found in overseas 
studies of DAA.8,9 such requests may cause 
tension in patient-doctor relationships and valuable 
 if the participant or someone they knew well had 
suffered from the advertised health condition then 
they were significantly more likely to agree that they 
would take action compared with those without 
personal experience of the condition (Table 4). this 
was particularly the case for intention to ask for a 
prescription or referral, with 57.3% of participants 
with personal experience reporting this intention 
compared with 39.3% of those without (p<0.001).
Perceived severity and susceptibility
Participants perceived both conditions to be severe 
(mean score of 4.53 for fibromyalgia and 4.42 for 
osteopaenia on a six point scale). there was no 
significant difference between scores for the two 
conditions. When asked to rate how likely it would 
be that they would experience the advertised 
conditions (on a six point scale), participants 
perceived themselves to be susceptible to both 
conditions (mean score of 3.40 for fibromyalgia 
and 3.88 for osteopaenia) but significantly more 
susceptible to osteopaenia (p=0.007). Just over 25% 
scale was 0.822, indicating an appropriate level 
of internal consistency. Data was analysed with 
sPss V15. Descriptive analysis was conducted and 
nonparametric tests were used as the data was not 
normally distributed.23
Results
A total of 977 women were approached to 
participate in the study, with 30% agreeing. 
however, only 82.5% of those who agreed were 
eligible. A total of 241 women aged 48–85 years 
(median age 64) participated in the survey. the 
demographic profile of participants was similar 
to women in this age group in the Wollongong 
local government area and Australian census data 
(except that a greater proportion of participants 
in the study had higher levels of educational 
attainment).
 Questionnaires were completed for a total of 
466 advertisements: 232 on fibromyalgia and 234 
on osteopaenia, and most participants rated the 
advertisements as easy to understand. only 36% 
of participants agreed that they or someone they 
knew well had suffered from fibromyalgia, but 64% 
agreed that they or someone they knew well had 
suffered from osteopaenia.
Behavioural intentions
Forty-nine percent of the participants agreed that 
they would ask their doctor for a prescription or 
referral as a result of seeing the advertisement, 
and the majority agreed that they would take other 
actions (Table 1).
 contingency table analysis indicated a 
statistically different result between reported 
behavioural intentions for the two different health 
conditions: participants viewing the advertisement 
for osteopaenia were more likely to report an 
intention to talk to their doctor about the condition 
(p=0.029) and to ask their doctor about treatments 
or tests (p=0.024) (Table 2).
 Behavioural intentions did not differ significantly 
between the sponsor manipulations. Participants 
who viewed low information advertisements were 
more likely to report an intention to ask their doctor 
for a prescription or a referral (p=0.036) than those 
who viewed high information advertisements (Table 
3). mann-Whitney u tests showed that participants 
who intended to ask for a prescription or referral 
were more likely to be older (p<0.001), and less 
educated (p<0.001).
Table 1. Behavioural intention by advertisement
Behavioural intention Percentage – including all 
advertisements (n=466)
As a result of seeing this advertisement would you…?
Talk to your doctor about the condition 77%
Ask your doctor about treatments or tests 73%
Look for information as directed by the advertisement 64%
Look for information from other sources 55%
Ask your doctor for a prescription or a referral 49%
Do nothing 23%
Table 2. Behavioural intention by condition type
Behavioural intention Condition type c2







Talk to your doctor about the 
condition
73.1% 81.7% 0.029
Ask your doctor about treatments 
or tests
68.3% 77.8% 0.024
Look for information as directed by 
the advertisement
63.1% 65.5% 0.596
Look for information from other 
sources
55.0% 55.5% 0.916
Ask your doctor for a prescription 
or a referral
45.1% 52.5% 0.123
Do nothing 25.0% 20.6% 0.291
Disease awareness advertising – women’s intentions following exposure research
146  Reprinted from AustRAliAn FAmily PhysiciAn Vol.40, no. 3, mARch 2011
how they would view magazine advertisements in 
a ‘real life’ context. Further research is required to 
determine whether reported intentions to speak 
with GPs and request a prescription or referral 
articulate into actual behaviour. 
 other limitations include sampling by intercept 
method which attracts a level of response bias 
and results may not be representative of all 
Australian women in this age group. Due to the 
limited nature and size of the sample, the findings 
should be interpreted with caution and may not 
be generalisable to the Australian population. it is 
possible that participants confused the advertised 
condition ‘osteopaenia’ with the better known 
condition ‘osteoporosis’. this may have led to a 
greater perceived severity and susceptibility to 
the condition, increased agreement for personal 
experience with the condition, and intention to 
take action.
 Further studies are required with true DAA for 
a range of health conditions, utilising larger and 
more representative samples to confirm these 
results. however, results of this study indicate 
the potential for DAA to influence patients to 
request prescription medicine or a referral from 
their doctor. in the current study, the effects were 
most pronounced in older, less educated women, 
along with those reporting personal experience 
with the health condition and those viewing 
advertisements with limited disease information. 
medicines Australia has the opportunity to provide 
more detailed guidance regarding the amount 
and types of disease information to be included 
in industry DAA to help ensure it is of greater 
educational value, and does not serve as a method 
of stimulating demand for prescription medicines.
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data suggests that 2–10% of women have the 
condition.26 similarly, 36% estimated that it was 
very likely that they would experience osteopaenia, 
however, an Australian study of women aged 
over 50 years found a prevalence of 15%.27 While 
participants were not asked about their perceived 
susceptibility to the conditions before being shown 
the stimuli, the results suggest that providing more 
detailed prevalence and risk factor information 
in DAA may help consumers to more accurately 
identify their susceptibility. Participants that 
reported an intention to ask for a prescription or 
referral perceived a higher level of susceptibility 
to, and severity of, the health conditions. these 
results provide some support for the argument 
that DAA can be seen as disease mongering and 
can inflate perceptions of the prevalence of the 
advertised disease.3
Study limitations
A limitation of this study is that participants’ 
involvement with the stimuli would be different to 
consultation time may be spent re-educating 
patients, as has been found for DtcA.24 A recent 
survey found that the majority of Australian GPs 
who received patient requests about a medication 
as a result of DAA were opposed to these 
advertising campaigns.10
 the results have important implications for 
regulation in Australia as they indicate that DAA 
can stimulate patients’ intention to make requests 
to doctors for prescription medicine products, 
particularly if limited disease information is 
provided. While the effect of the more specific 
guidelines for DAA in medicines Australia’s code 
of conduct, edition 16 are yet to be determined, 
regulators should provide more guidance to 
advertisers regarding types of disease information 
and the level of detail that should be provided. 
more prescriptive guidelines are provided in other 
countries such as the united Kingdom.25
 Just over one-quarter of participants estimated 
that it was very likely that they would experience 
fibromyalgia in the future, whereas international 
Table 3. Behavioural intention by information manipulation
Behavioural intention Information level c2





Talk to your doctor about the condition 73.8% 78.5% 0.311
Ask your doctor about treatments or tests 66.7% 75.0% 0.092
Look for information as directed by the advertisement 58.5% 66.1% 0.155
Look for information from other sources 48.1% 57.4% 0.092
Ask your doctor for a prescription or a referral 39.8% 51.7% 0.036
Do nothing 25.8% 21.9% 0.432
Table 4. Behavioural intention by personal experience




c2  p value
As a result of seeing this 
advertisement would you…?
Talk to your doctor about the 
condition
83.1% 71.4% 0.004
Ask your doctor about treatments 
or tests
77.9% 68.1% 0.022
Look for further information as 
directed by the advertisement
69.0% 58.8% 0.028
Look for further information from 
other sources
61.4% 49.1% 0.010
Ask your doctor for a prescription 
or referral
57.3% 39.3% 0.000
Do nothing 16.8% 28.6% 0.006
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